Biomarin Pharmaceutical (BMRN) Interest Coverage Ratio Growth (3y) (2012 - 2026)
Powered by 
Analysis
Biomarin Pharmaceutical (BMRN) Interest Coverage Ratio Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 29.79% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -44.22% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 33.30% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -35.50% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 81.16% |
| 10 | Biomarin Pharmaceutical | 12.88 Bn | 12.01 Bn | 786.91 Mn | -53.53% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -53.53% |
| Mar 31, 2026 | -19.88% |
| Dec 31, 2025 | -64.47% |
| Sep 30, 2025 | -227.26% |
| Jun 30, 2025 | 116.78% |
| Mar 31, 2025 | 29.41% |
| Dec 31, 2024 | 78.18% |
| Sep 30, 2024 | 68.57% |
| Jun 30, 2024 | 122.54% |
| Mar 31, 2024 | 55.80% |
| Dec 31, 2023 | 34.12% |
| Sep 30, 2023 | 50.16% |
| Jun 30, 2023 | 75.79% |
| Mar 31, 2023 | 3.55% |
| Dec 31, 2022 | -39.76% |
| Sep 30, 2022 | -33.48% |
| Jun 30, 2022 | 54.45% |
| Mar 31, 2022 | 86.62% |
| Dec 31, 2021 | -51.51% |
| Sep 30, 2021 | -119.65% |